2022 年第三季度报告 单位：元 币种：人民币 证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|----------------------------------|------------------|----------------------- ...

Financial Performance - Haohai Biotechnology reported a revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[1]. - The company achieved a net profit of RMB 300 million, with a profit margin of 25%[1]. - The company's operating revenue for the first half of 2022 was approximately ¥967.79 million, representing a 13.69% increase compared to ¥851.23 million in the same period last year[12]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥71.03 million, a significant decrease of 69.25% from ¥231.02 million in the previous year[12]. - The overall gross profit margin for the reporting period was 69.84%, down from 74.53% in the same period last year, primarily due to lower margins from subsidiaries in the RF and laser equipment industry[60]. - The company reported a net cash flow from operating activities of approximately ¥114.76 million, a decrease of 4.99% from ¥120.79 million in the same period last year[12]. - The company incurred approximately RMB 48.35 million in losses due to production stoppages during the Shanghai lockdown from March to May 2022[61]. - The company reported a net profit of 71,029,961.51 RMB for the first half of 2022, with a comprehensive income total of 30,662,115.44 RMB[164]. Research and Development - Haohai Biotechnology is investing RMB 500 million in R&D for advanced biomaterials over the next two years[1]. - The company has increased its R&D investment to develop new technologies and products, focusing on core technology transformation and collaboration with renowned universities and hospitals[35]. - The company has developed a comprehensive range of intraocular lens technologies and products, including PMMA, hydrophilic, and hydrophobic materials, as well as optical designs and additional functionalities[40]. - The company has successfully developed the world's first medical chitosan product for human use, which won the "National Science and Technology Progress Second Prize"[39]. - The company has received product approvals for 14 R&D projects, with several products achieving domestic and international leading technology levels[48]. - The R&D team consists of 312 members, accounting for approximately 16.72% of the total workforce, including 22 PhDs and 76 Master's degree holders, indicating a strong focus on innovation[54]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - Future guidance estimates a revenue growth of 20% for the full year 2022, driven by new product launches and market expansion[1]. - The company is focused on becoming a leading enterprise in the field of biomedical materials through technological innovation and resource integration[18]. - The company plans to expand its product lines in ophthalmology and medical aesthetics through increased R&D investment and market integration strategies[63]. - The company is actively integrating resources with partners to strengthen its technological capabilities and product competitiveness in the biomedical field[82]. Product Development and Innovation - New product development includes a novel intraocular lens expected to launch in Q4 2022, projected to generate RMB 200 million in revenue[1]. - The company has completed clinical trials for a new type of OK lens product and is currently in the registration application phase[20]. - The company has developed a range of surgical adhesion prevention products and is a leading manufacturer of medical collagen sponge products in China[26]. - The company has developed a new bionic hydrogel material, with a total investment of ¥300.00 million, currently in preclinical research, aimed at improving comfort for contact lens wearers[48]. - The company’s PRL product for myopia correction has independent intellectual property rights and is the only domestic product approved for severe myopia correction, with a significant market opportunity[70]. Financial Stability and Assets - Haohai Biotechnology maintains a strong cash position with RMB 1 billion in liquid assets, ensuring financial stability for upcoming projects[1]. - The company's total assets at the end of the reporting period were approximately ¥7.01 billion, a slight increase of 0.93% from ¥6.95 billion at the end of the previous year[12]. - The company's net assets attributable to shareholders decreased by 3.05% to approximately ¥5.54 billion from ¥5.71 billion at the end of the previous year[12]. - The company has established a centralized procurement center to enhance operational efficiency and reduce costs, focusing on supplier quality and procurement processes[27]. Risks and Challenges - The company has identified key risks including regulatory changes and market competition, which may impact future performance[1]. - The company faced significant production impacts due to the COVID-19 pandemic in Shanghai, resulting in over ¥90 million in losses from reduced gross profit and downtime[13]. - The company faces risks related to market competition, regulatory changes, and potential integration challenges from recent acquisitions[85][86]. Environmental and Compliance - The company and its subsidiary Likangrui are classified as key pollutant discharge units, with no instances of exceeding discharge concentration or total amount during the reporting period[117]. - The company has completed the construction of supporting environmental protection facilities, including wastewater treatment and air emission terminal treatment facilities, which are operating normally and meeting discharge standards[119]. - Continuous online monitoring of key pollutants in wastewater and air emissions is conducted, with data subject to supervision by environmental authorities[123]. Shareholder and Governance - The proposal for the issuance of A-shares was approved by over two-thirds of the voting rights at the 2021 Annual General Meeting and the 2022 Second A-share Class General Meeting, but failed to pass at the 2022 Second H-share Class General Meeting[109]. - The company has committed to a lock-up period of at least 6 months for its A-shares following the IPO, with specific conditions for share reduction thereafter[127]. - The company has pledged to notify the issuer of any competitive business opportunities obtained from third parties and to ensure that controlled enterprises do not engage in competing activities[128].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 473,617,820.88, representing a year-on-year increase of 23.79%[2] - The net profit attributable to shareholders decreased by 37.17% to RMB 60,941,331.70, primarily due to production challenges and fixed cost allocation[5] - The net profit for Q1 2022 was CNY 63,476,862.60, a decrease of 36.2% compared to CNY 99,315,085.73 in Q1 2021[15] - The basic and diluted earnings per share were both RMB 0.35, reflecting a decline of 36.36%[2] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.35, down from CNY 0.55 in Q1 2021[16] - The total comprehensive income for Q1 2022 was CNY -12,480,097.16, contrasting with CNY 120,373,389.52 in Q1 2021[15] Cash Flow and Liquidity - The net cash flow from operating activities fell by 71.36% to RMB 4,470,962.15, influenced by increased wage payments and raw material procurement costs[7] - Cash flow from operating activities generated CNY 4,470,962.15, a decline of 71.4% from CNY 15,609,445.06 in the previous year[16] - Cash and cash equivalents as of March 31, 2022, were CNY 2,697,254,015.40, down from CNY 2,901,402,136.28 at the end of 2021[11] - Cash and cash equivalents at the end of Q1 2022 totaled CNY 988,400,664.79, down from CNY 1,327,887,460.94 at the beginning of the period[17] - The company maintained a strong liquidity position with current assets totaling CNY 3,585,776,992.44 as of March 31, 2022[11] Assets and Liabilities - Total assets at the end of the reporting period were RMB 6,854,436,764.22, a decrease of 1.38% compared to the end of the previous year[3] - Total assets as of March 31, 2022, amounted to CNY 6,854,436,764.22, a slight decrease from CNY 6,950,355,416.19 at the end of 2021[12] - Total liabilities as of March 31, 2022, were CNY 835,467,406.99, down from CNY 890,070,458.09 at the end of 2021[12] Research and Development - R&D investment totaled RMB 45,520,090.97, accounting for 9.61% of operating revenue, an increase of 0.06 percentage points year-on-year[3] - Research and development expenses increased to CNY 45,520,090.97 in Q1 2022, compared to CNY 36,527,079.45 in Q1 2021, reflecting a growth of 24.5%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,295[8] - The largest shareholder, Jiang Wei, held 25.28% of the shares, totaling 44,449,000 shares[8] Other Financial Metrics - The weighted average return on net assets was 1.08%, down by 0.67 percentage points[3] - The company reported non-recurring gains of RMB 1,858,769.15 for the period[4] - The company reported a net profit margin improvement, with net profit for Q1 2022 reflecting operational efficiency gains[13] - Inventory as of March 31, 2022, was CNY 376,825,300.32, an increase from CNY 354,765,098.16 at the end of 2021[11] - The company reported a decrease in other comprehensive income after tax, amounting to CNY -75,956,959.76 in Q1 2022, compared to CNY 21,058,303.79 in Q1 2021[15] - Investment income from associates and joint ventures was CNY 1,200,000.00 in Q1 2022, a substantial increase from CNY 138,062.36 in Q1 2021[15] Future Outlook - The company plans to continue investing in new product development and market expansion strategies in the upcoming quarters[10]

[Important Notice and Financial Summary](index=2&type=section&id=%E9%87%8D%E8%A6%81%E5%85%A7%E5%AE%B9%E6%8F%90%E7%A4%BA) [Key Financial Data and Indicators](index=2&type=section&id=%E4%B8%80%E3%80%81%E4%B8%BB%E8%A6%81%E6%9C%83%E8%A8%88%E6%95%B8%E6%93%9A%E5%92%8C%E8%B2%A1%E5%8B%99%E6%8C%87%E6%A8%99) In Q1 2022, the company's operating revenue increased by 23.79% year-on-year, but net profit attributable to shareholders significantly decreased by 37.17%, with net cash flow from operating activities also down 71.36% Key Financial Performance Indicators | Indicator | Q1 2022 | YoY Change (%) | | :--- | :--- | :--- | | **Operating Revenue** | 473,617,820.88 Yuan | 23.79% | | **Net Profit Attributable to Shareholders of the Listed Company** | 60,941,331.70 Yuan | -37.17% | | **Net Profit Attributable to Shareholders of the Listed Company, Excluding Non-Recurring Gains and Losses** | 59,082,562.55 Yuan | -36.48% | | **Net Cash Flow from Operating Activities** | 4,470,962.15 Yuan | -71.36% | | **Basic Earnings Per Share (Yuan/share)** | 0.35 Yuan | -36.36% | | **Weighted Average Return on Net Assets (%)** | 1.08% | Decrease of 0.67 percentage points | Key Financial Position Indicators | Indicator | March 31, 2022 | Change from End of Previous Year (%) | | :--- | :--- | :--- | | **Total Assets** | 6,854,436,764.22 Yuan | -1.38% | | **Total Equity Attributable to Shareholders of the Listed Company** | 5,616,540,791.70 Yuan | -1.70% | [Non-Recurring Gains and Losses Items](index=3&type=section&id=%EF%BC%88%E4%BA%8C%EF%BC%89%E9%9D%9E%E7%B6%93%E5%B8%B8%E6%80%A7%E6%90%8D%E7%9B%8A%E9%A0%85%E7%9B%AE%E5%92%8C%E9%87%91%E9%A1%8D) During the reporting period, total non-recurring gains and losses amounted to approximately 1.86 million Yuan, primarily from government grants and fair value changes of financial assets Non-Recurring Gains and Losses Details | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | 56,003.42 | | Government Grants Included in Current Profit/Loss | 1,774,258.81 | | Gains/Losses from Fair Value Changes of Financial Assets Held for Trading | 596,220.58 | | Other Non-Operating Income and Expenses | 188,528.68 | | Less: Income Tax Impact | 144,781.29 | | Less: Impact on Minority Interests (After Tax) | 611,461.05 | | **Total** | **1,858,769.15** | [Analysis of Changes in Key Financial Indicators](index=4&type=section&id=%EF%BC%88%E4%B8%89%EF%BC%89%E4%B8%BB%E8%A6%81%E6%9C%83%E8%A8%88%E6%95%B8%E6%93%9A%E3%80%81%E8%B2%A1%E5%8B%99%E6%8C%87%E6%A8%99%E7%99%BC%E7%94%9F%E8%AE%8A%E5%8B%95%E7%9A%84%E6%83%85%E5%86%B5%E3%80%81%E5%8E%9F%E5%9B%A0) The significant decline in net profit and EPS is primarily due to reduced investment-related income, while decreased operating cash flow resulted from increased employee compensation and raw material procurement - Net profit attributable to shareholders and non-recurring net profit both decreased by over **36%** year-on-year, mainly because the previous year recognized deemed disposal gains from associates and received investment dividends, which were not received in the current reporting period[6](index=6&type=chunk) - Net cash flow from operating activities decreased by **71.36%** year-on-year, primarily due to increased payment of wages and bonuses payable from the end of the previous year, and increased procurement payments for raw material stocking to address supply chain challenges[6](index=6&type=chunk) [Shareholder Information](index=5&type=section&id=%E4%BA%8C%E3%80%81%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%B1%E4%BF%A1%E6%81%AF) [Total Number of Shareholders and Shareholding of Top Ten Shareholders](index=5&type=section&id=%EF%BC%88%E4%B8%80%EF%BC%89%E6%9C%AC%E5%85%AC%E5%8F%B8%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E6%9D%B1%E7%B8%BD%E6%95%B8%E5%92%8C%E8%A1%A8%E6%B1%BA%E6%AC%8A%E6%81%A2%E5%BE%A9%E7%9A%84%E5%84%AA%E5%85%88%E8%82%A1%E8%82%A1%E6%9D%B1%E6%95%B8%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E6%9D%B1%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) As of the reporting period end, the company had 11,295 common shareholders, with controlling shareholder Mr. Jiang Wei and his spouse Ms. You Jie holding 41.66% combined, and HKSCC NOMINEES LIMITED as the second largest shareholder - As of the end of the reporting period, the company had **11,295** common shareholders[7](index=7&type=chunk) Top Ten Shareholders' Shareholding | Shareholder Name | Shareholding Percentage (%) | Number of Shares Held (shares) | Nature of Shares | | :--- | :--- | :--- | :--- | | Jiang Wei | 25.28 | 44,449,000 | Domestic Natural Person | | HKSCC NOMINEES LIMITED | 21.58 | 37,948,789 | Other | | You Jie | 16.38 | 28,800,000 | Domestic Natural Person | | Lou Guoliang | 4.05 | 7,125,075 | Overseas Natural Person | | Shanghai Zhanze Enterprise Management Partnership (Limited Partnership) | 3.68 | 6,471,000 | Domestic Non-State-Owned Legal Person | - Among the top ten shareholders, Jiang Wei and You Jie are spouses and are the company's controlling shareholder and actual controller. Shanghai Zhanze Enterprise Management Partnership (Limited Partnership) is an enterprise controlled by Jiang Wei[10](index=10&type=chunk)[11](index=11&type=chunk) [Financial Statements](index=7&type=section&id=%E5%9B%9B%E3%80%81%E7%AC%AC%E4%B8%80%E5%AD%A3%E5%BA%A6%E8%B2%A1%E5%8B%99%E5%A0%B1%E8%A1%A8) [Consolidated Balance Sheet](index=7&type=section&id=%E5%90%88%E4%BD%B5%E8%B3%87%E7%94%A2%E8%B2%A0%E5%82%B5%E8%A1%A8) As of March 31, 2022, total assets were 6.85 billion Yuan, a slight decrease of 1.38% from year-end, with cash decreasing while inventory and accounts receivable increased. Total liabilities decreased to 835.47 million Yuan Key Asset Items | Key Asset Item | March 31, 2022 (Yuan) | December 31, 2021 (Yuan) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 2,697,254,015.40 | 2,901,402,136.28 | | Accounts Receivable | 399,705,182.28 | 370,503,253.97 | | Inventories | 376,825,300.32 | 354,765,098.16 | | **Total Assets** | **6,854,436,764.22** | **6,950,355,416.19** | Key Liabilities and Equity Items | Key Liabilities and Equity Item | March 31, 2022 (Yuan) | December 31, 2021 (Yuan) | | :--- | :--- | :--- | | Short-Term Borrowings | 2,000,000.00 | 25,184,398.63 | | Employee Benefits Payable | 53,724,654.27 | 78,697,949.25 | | **Total Liabilities** | **835,467,406.99** | **890,070,458.09** | | **Total Equity Attributable to Parent Company Shareholders** | **5,616,540,791.70** | **5,713,459,639.49** | [Consolidated Income Statement](index=9&type=section&id=%E5%90%88%E4%BD%B5%E5%88%A9%E6%BD%A4%E8%A1%A8) Q1 2022 operating revenue grew 23.79% to 473.62 million Yuan, but significant increases in operating costs, selling, and administrative expenses, coupled with an 83.17% drop in investment income, led to a 37.17% decline in net profit Consolidated Income Statement Highlights | Item | Q1 2022 (Yuan) | Q1 2021 (Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | **Total Operating Revenue** | **473,617,820.88** | **382,585,206.31** | **+23.79%** | | Operating Cost | 156,221,109.72 | 96,511,274.44 | +61.87% | | Selling Expenses | 148,064,767.78 | 122,111,278.28 | +21.25% | | Administrative Expenses | 75,239,783.34 | 49,667,248.47 | +51.49% | | Research and Development Expenses | 45,520,090.97 | 36,527,079.45 | +24.62% | | Investment Income | 2,313,643.50 | 13,750,368.57 | -83.17% | | **Operating Profit** | **69,617,649.65** | **114,812,074.20** | **-39.36%** | | **Net Profit Attributable to Parent Company Shareholders** | **60,941,331.70** | **96,992,749.11** | **-37.17%** | [Consolidated Cash Flow Statement](index=11&type=section&id=%E5%90%88%E4%BD%B5%E7%8F%BE%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Net cash flow from operating activities significantly decreased to 4.47 million Yuan due to increased payments for goods and employee compensation, while investing and financing activities also resulted in net outflows, leading to a lower period-end cash balance Consolidated Cash Flow Statement Highlights | Item | Q1 2022 (Yuan) | Q1 2021 (Yuan) | | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | **4,470,962.15** | **15,609,445.06** | | **Net Cash Flow from Investing Activities** | **-174,414,144.19** | **-717,296,418.52** | | **Net Cash Flow from Financing Activities** | **-121,583,632.57** | **-1,377,033.95** | | Effect of Exchange Rate Changes on Cash | -3,965,472.94 | 1,826,678.69 | | **Net Increase in Cash and Cash Equivalents** | **-295,492,287.55** | **-701,237,328.72** | | Cash and Cash Equivalents at Beginning of Period | 1,283,892,952.34 | 1,327,887,460.94 | | **Cash and Cash Equivalents at End of Period** | **988,400,664.79** | **626,650,132.22** |

Financial Performance - The company's revenue for 2021 was approximately RMB 1.77 billion, representing a 32.61% increase compared to RMB 1.33 billion in 2020[16]. - The net profit attributable to shareholders for 2021 was approximately RMB 352.24 million, a 53.10% increase from RMB 230.07 million in 2020[16]. - The net cash flow from operating activities for 2021 was approximately RMB 342.29 million, reflecting a 30.61% increase compared to RMB 262.07 million in 2020[16]. - The total assets at the end of 2021 were approximately RMB 6.95 billion, a 10.35% increase from RMB 6.30 billion at the end of 2020[16]. - The company's net assets attributable to shareholders at the end of 2021 were approximately RMB 5.71 billion, a 4.06% increase from RMB 5.49 billion at the end of 2020[16]. - The basic earnings per share for 2021 were RMB 2.00, a 53.85% increase from RMB 1.30 in 2020[17]. - The diluted earnings per share for 2021 were RMB 2.00, consistent with the basic earnings per share[17]. - The net profit after deducting non-recurring gains and losses for 2021 was approximately RMB 327.96 million, a 58.88% increase from RMB 206.43 million in 2020[16]. - The total amount of non-recurring gains and losses was 24,270,714.28 RMB, showing a slight increase from 2020[21]. Dividend and Share Capital - The company plans to distribute a cash dividend of 7.00 CNY per 10 shares, totaling approximately 123.08 million CNY, which accounts for 34.94% of the net profit attributable to shareholders for the year 2021[3]. - The total share capital of the company as of the report date is 175,822,100 shares[3]. - The company does not plan to increase capital reserves or issue bonus shares[3]. Corporate Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors and senior management confirm the authenticity, accuracy, and completeness of the annual report[2]. - There are no significant non-operating fund occupations by controlling shareholders or related parties[4]. - There are no violations of decision-making procedures regarding external guarantees[5]. - The company has not disclosed any special arrangements for corporate governance[5]. - The report includes a forward-looking statement risk declaration, indicating potential risks in future plans and strategies[4]. Research and Development - The R&D expenditure as a percentage of revenue for 2021 was 9.48%, slightly down from 9.49% in 2020[17]. - The company reported a significant increase in R&D expenditure compared to 2020, contributing to future growth despite rising operational costs[18]. - The company has increased its R&D investment to develop new technologies and products, focusing on collaboration with renowned universities and research institutions[67]. - The company has a comprehensive R&D project management system, primarily relying on its internal teams for product development[67]. - The company has developed a range of core technologies, including the BioVue® surface modification technology for artificial lenses and innovative preparation techniques for hyaluronic acid products[70]. - The company has filed for 42 new patents during the reporting period, with a total of 311 patents granted to date[78]. - The company is currently developing 22 projects, with 11 projects in clinical trials and 11 in preclinical research stages[83]. Market Performance and Strategy - The company maintained a 45.24% market share in the ophthalmic viscoelastic device market in China, leading the market for 14 consecutive years[26]. - The company is focusing on expanding its product lines in ophthalmology and medical aesthetics, with new products entering clinical trials and ongoing development of innovative solutions[24]. - The company achieved total revenue of RMB 1,766.99 million in 2021, an increase of RMB 434.57 million, representing a growth rate of 32.61% compared to the previous year[23]. - The company is the largest producer of orthopedic joint cavity viscoelastic supplements in China, with a market share that has grown from 42.06% in 2019 to 43.30% in 2020[44]. - The company is exploring new strategies in market expansion and product development, particularly in the field of ophthalmic and orthopedic treatments[83]. Acquisitions and Investments - The company acquired 55% of Hengtai Vision and secured exclusive distribution rights for high-end corneal reshaping contact lenses in mainland China, enhancing its market presence[33]. - The company acquired 60% of Hebei Xinkang, which has approved medical device registrations for various soft contact lenses, facilitating the production of new myopia control products[36]. - The group acquired a 63.64% stake in Euroha Medical for RMB 205 million, expanding its product offerings in the field of radiofrequency and laser medical beauty devices[41]. - The company plans to invest up to USD 31 million in Eirion for exclusive rights to develop and commercialize innovative botulinum toxin products in Greater China[42]. Financial Position and Cash Flow - The net cash flow from investing activities turned negative at -148.09 million RMB, a significant decrease compared to the previous year's positive cash flow[119]. - The net cash flow from financing activities also increased to -231.25 million RMB, mainly due to the repayment of short-term bank loans[119]. - The company reported a financial net income of 84.85 million RMB, a decrease of 14.40% due to declining deposit interest rates[118]. - The company’s total assets at the end of the reporting period amounted to 6,949,000,000.00 CNY, with a significant increase in inventory by 39.05% to 354,765,098.16 CNY due to proactive procurement strategies[121]. Market Trends and Opportunities - The company anticipates continued growth in the ophthalmology market, driven by increasing health awareness and payment capabilities among consumers[127]. - The market size for orthopedic joint cavity viscoelastic supplements in China was approximately CNY 1.837 billion in 2020, a year-on-year decrease of 14.4%, and is expected to grow to CNY 2.111 billion by 2026, with a CAGR of about 1.9% from 2021 to 2026[132]. - The Chinese medical beauty market size is expected to reach CNY 184.6 billion in 2021, with a year-on-year growth of over 20%[130]. - The number of myopia patients in China has exceeded 600 million, with the youth myopia rate being the highest in the world, indicating a significant market demand for myopia prevention and correction products[129]. Management and Governance - The company has appointed several directors and executives across various subsidiaries, including positions in Haohai Holdings and Haohai Cayman, indicating a strong leadership structure[187]. - The management team includes individuals with extensive experience in the medical technology field, which may contribute to future innovations and product developments[188]. - The company has maintained a consistent presence in the market with key personnel serving in their roles for several years, ensuring stability and continuity in leadership[187]. - The company has established specialized committees, including an audit committee and a strategic committee, to enhance governance[196].

2021 年第三季度报告 单位：元 币种：人民币 证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|------------------|------------------------ ...